HIV
Read Time: 3 mins

Cabotegravir and Rilpivirine Long-acting Injectable Therapy for Human Immunodeficiency Virus

Published Online: August 24th 2022 touchREVIEWS in Infectious Diseases. 2022;1(1):Online ahead of journal publication
Authors: Celia Jonsson-Oldenbüttel
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Celia Jonsson-Oldenbüttel
Dr. med. Dr. phil. Celia Jonsson-Oldenbüttel is a general practicioner specializing in human immunodeficiency virus (HIV) with expertise in clinical HIV research. She is the medical director of MVZ Munich, one of the biggest outpatient clinics for patients infected with HIV in Europe. She holds a medical doctor degree from Medical University TUM, Munich, and a doctor degree of philosophy from the University of Heidelberg.

Keywords

Antiretroviral therapy, HIV infection, injectables, long-acting therapy

Article:

Combination antiretroviral therapy has significantly improved the life expectancy of people living with human immunodeficiency virus type 1 (HIV-1) infection, but requires daily oral therapy.1 In 2021, CABENUVA (ViiV Healthcare, Brentford, UK), the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults, received regulatory approval, based on the findings of the phase III ATLAS (Antiretroviral therapy as long-acting suppression) and FLAIR (First long-acting injectable regimen) studies.2,3

In an expert interview, Celia Jonsson-Oldenbüttel discusses the advantages of this long-acting treatment regimen and the challenges of its implementation.

Q. What is the incidence of virological treatment failure in HIV therapy and what factors can predict treatment failure?

In recent years we have seen a very low rate of treatment failure. Around 95% of patients achieve viral suppression, which means HIV mRNA below 50 copies. Unfortunately we do not know all the factors that can predict treatment failure, but those we know include previous evidence of viral resistances and problems with adherence to daily dosing..

Q. Could you tell us a little about CABENUVA and its indications for use?

In Germany, this long-acting HIV therapy was approved in May 2021. It comprises intramuscular injections of cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor, which are administered every 8 weeks. The injections create a deposit in the muscles, which is released slowly over 8 weeks. The indications for this therapy are an HIV virus load below 50 copies/mL, no history of virological treatment failure, and no current or previous evidence of viral resistance against the medication. Current evidence shows that not every patient with HIV is suitable for this therapy; we have learned that even the treating physician cannot predict which patients will be suitable. It is important to make the patient aware of this new therapy form. A switch to injection therapy should only be made if the patient has a specific reason and wish to do so. There are many medical and personal reasons for injection therapy, and it is notable that a large proportion of women and people of other ethnic groups with different cultural backgrounds show great interest in injection therapy.

Q. What are the advantages of taking daily CABENUVA over daily oral therapy from both a medical and patient-oriented point of view?

Long-acting therapy is considered to be safe and non-inferior to daily therapy. Long-acting therapy generates a high level of acceptance and satisfaction among patients, and we see advantages among patients with medical problems such as malabsorption, bulimia, dysphagia and renal dysfunction. We also see advantages in patients with psychiatric disorders such as Alzheimer’s disease and other dementias. If patients take additional medications with high potential to interact with the HIV therapy, it is also advantageous to take long-acting therapy.

From the patient-oriented point of view, there is a safety factor in forgetting to take the pills, it is useful for patients who have adherence problems with daily dosing, and patients do not get a daily reminder of HIV infection and therefore stigma. Integration of daily tablet-taking into everyday life is a big problem for many people, such as shift workers and flight attendants. The stigmatization in social and professional environments is a very important factor. In addition, after taking oral therapy for many years, patients can develop tablet fatigue.

Q. What factors should be considered before prescribing CABENUVA?

First, we need a good reason from the point of view of the patient. We need the patient’s resistance profile before starting therapy, we need to exclude hepatitis B, and we have to make sure the patient is aware of the potential injection-site reaction, which can involve pain, redness and swelling. We have to schedule the intramuscular injections every 2 months with a deviation of ±7 days, resulting in a higher number of physician visits. If the patient is on vacation or has coronavirus disease 2019 and cannot meet this appointment, we have to arrange bridging therapy, ensuring that they have other tablets with them. In Germany, we also have to discuss the higher cost with the patient before initiating therapy, because it is more expensive.

Q. What barriers are there to successful implementation of CABENUVA in everyday clinical practice and how might they be overcome?

Implementation of injection therapy in everyday clinical practice is associated with various challenges for the patient, as well as the clinical and nursing team. First, injection deployment has to be scheduled, necessitating a good computer record system and a system that issues reminders if an appointment is missed. The drugs have to be stored in a refrigerator and therefore there is a need for a pharmacy that can provide this. Incorrect injection leads to pain and, in the worst-case scenario, the failure of the therapy. Well-trained staff are needed. In patients who are obese (body mass index >30), longer needles are needed in order to ensure the drug enters the muscle and not the fat. It is essential to have adrenaline on hand in case a patient has a severe reaction. The first two injections are given monthly and the 8-week injection schedule may deviate by 7 days, potentially requiring bridging therapy as mentioned above.

Article Information:
Disclosure

Celia Jonsson-Oldenbüttel has received speech and congress support from AbbVie, Gilead Sciences, Janssen-Cilag and ViiV Healthcare/GSK. She has also served on the advisory board for Gilead Sciences, Janssen-Cilag, MSD and ViiV Healthcare/GSK.

Compliance With Ethics

This article is an interview and did not involve any studies with human or animal subjects performed by the author.

Review Process

This is an expert interview and, as such, has not undergone the journal’s standard peer-review process.

Authorship

The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.

Correspondence

Celia Jonsson-Oldenbüttel, MVZ Munich at Goetheplatz, Waltherstr. 32, 80337 Munich, Germany. E: jonssoncelia@gmail.com

Support

No funding was received in the publication of this article.

Access

This article is freely accessible at touchINFECTIOUSDISEASES.com. © Touch Medical Media 2022

Acknowledgements

Medical writing assistance was provided by Katrina Mountfort, freelancer, and funded by Touch Independent Medical Education.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.

Received

2022-07-21

References

  1. Solomon DA, Sax PE. Current state and limitations of daily oral therapy for treatment. Curr Opin HIV AIDS. 2015;10:219–25.
  2. Swindells S, Andrade-Villnueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112–23.
  3. Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124–35.

Further Resources

Share this Article
Related Content In HIV
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72